BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition
Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus ...
Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus ...
BioMarin said Friday it would purchase Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...
The 62 children who were found to have the rare "Bubble Boy disease" as babies and toddlers between 2012 and ...
The FDA has halted clinical testing of an Intellia Therapeutics gene-editing therapy following a report that a patient in a ...
In a case that was billed as profits versus patients, India’s Supreme Court dismissed a petition in which Roche sought ...
An experimental gene therapy from Sarepta Therapeutics increased levels of the gene missing in an ultra-rare form of muscular dystrophy, ...
In the five years since Italy-based Chiesi Group established its rare disease division in Boston, the unit has landed regulatory ...
Drugs for the rare hormone disorder acromegaly include older engineered peptides administered as frequent injections. A new FDA approval brings ...
Kent Kanouse / Flickr cc People who live with or handle pet bearded dragons are at continued risk for Salmonella ...
Tumors caused by recurrent respiratory papillomatosis are benign, but that doesn’t mean they are not serious. In this rare disease, ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.